DAFNA Capital Management Increases Biohaven Stake
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy BHVN?
Source: NASDAQ.COM
- Increased Holdings: DAFNA Capital Management acquired 720,000 shares of Biohaven in Q4 2025, with an estimated trade value of $8.92 million, indicating confidence in the company's future potential.
- Value Appreciation: By quarter-end, DAFNA's total stake value reached $10.78 million, up $7.25 million from the previous period, reflecting both stock price movements and the addition of new shares.
- Strategic Focus: Biohaven is cutting spending and narrowing its focus to three late-stage programs; despite a net loss of approximately $739 million last year, the company is undergoing a strategic transformation aimed at enhancing market competitiveness.
- Improved Liquidity: With about $322 million in cash at year-end and additional capital raised thereafter, Biohaven's financial position appears more stable than its stock price suggests, providing potential opportunities for future growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BHVN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BHVN
Wall Street analysts forecast BHVN stock price to rise
13 Analyst Rating
9 Buy
4 Hold
0 Sell
Moderate Buy
Current: 8.960
Low
11.00
Averages
18.00
High
30.00
Current: 8.960
Low
11.00
Averages
18.00
High
30.00
About BHVN
Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. It is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
DAFNA Capital Management Increases Biohaven Stake
- Increased Holdings: DAFNA Capital Management acquired 720,000 shares of Biohaven in Q4 2025, with an estimated trade value of $8.92 million, indicating confidence in the company's future potential.
- Value Appreciation: By quarter-end, DAFNA's total stake value reached $10.78 million, up $7.25 million from the previous period, reflecting both stock price movements and the addition of new shares.
- Strategic Focus: Biohaven is cutting spending and narrowing its focus to three late-stage programs; despite a net loss of approximately $739 million last year, the company is undergoing a strategic transformation aimed at enhancing market competitiveness.
- Improved Liquidity: With about $322 million in cash at year-end and additional capital raised thereafter, Biohaven's financial position appears more stable than its stock price suggests, providing potential opportunities for future growth.
See More
DAFNA Capital Increases Biohaven Stake by 720,000 Shares
- Share Increase: DAFNA Capital increased its stake in Biohaven by 720,000 shares during Q4 2025, with an estimated transaction value of $8.92 million, reflecting confidence in the company's future potential.
- Value Growth: Following this purchase, Biohaven's total stake value rose to $10.78 million, an increase of $7.25 million from the previous period, indicating the dual impact of stock price movements and additional shares.
- Portfolio Dynamics: Biohaven now represents 2.51% of DAFNA's reportable U.S. equity assets, highlighting its significance in the portfolio despite its overall poor performance.
- Company Transformation: Despite a net loss of approximately $739 million last year, Biohaven is focusing on three late-stage programs expected to yield important data this year, showcasing the company's potential and strategic adjustments during its transition.
See More
Biohaven Completes Enrollment in Obesity Treatment Clinical Trial
- Clinical Trial Enrollment Completed: Biohaven announced the completion of enrollment for its Phase 2 trial of taldefgrobep alfa, targeting approximately 150 participants, with topline data expected in the second half of 2026, potentially introducing a new treatment option for obesity.
- Efficacy Assessment Design: The trial employs a randomized, double-blind, placebo-controlled design to evaluate the monotherapy efficacy of taldefgrobep, primarily measuring weight change over 24 weeks, aiming to provide more effective treatment options for obese patients and potentially altering current treatment standards.
- Good Safety and Tolerability: Taldefgrobep has demonstrated good tolerability in over 700 clinical trial participants, with low rates of serious adverse events, indicating a promising outlook for its application in chronic weight management and positioning it as a next-generation obesity treatment.
- Innovative Mechanism and Market Potential: Taldefgrobep shows significant potential for improving body weight and fat mass by inhibiting activin receptor signaling, and its combination with GLP-1 agonists may open new market opportunities in obesity treatment, addressing the growing global demand for effective obesity therapies.
See More
Biohaven Completes Enrollment in Obesity Treatment Study
- Enrollment Completion: Biohaven announced the completion of enrollment in its Phase 2 study of taldefgrobep alfa for obesity, with topline data expected in the second half of 2026, marking a significant advancement in the company's obesity treatment efforts.
- Efficacy Assessment: The study will evaluate the efficacy of once-weekly and once-monthly taldefgrobep monotherapy, targeting approximately 150 participants, with primary measures focusing on weight change, reflecting the company's ongoing commitment to obesity treatment.
- Favorable Safety Profile: Taldefgrobep has demonstrated a favorable safety and tolerability profile in over 700 trial participants, with low rates of adverse events, establishing a solid foundation for its application in chronic weight management.
- Market Potential: The novel mechanism of taldefgrobep may provide significant benefits in fat reduction and muscle gain, with Biohaven believing it could offer new treatment options for obesity patients, further driving growth in the biopharmaceutical sector.
See More
Xenon Plans New Drug Application Submission
- Trial Results Exceed Expectations: Xenon announced that its azetukalner showed a median percent change of 53.2% in monthly focal onset seizure frequency at the 25 mg dose, significantly outperforming the placebo's 10.4%, which not only validates the drug's efficacy but also lays a solid foundation for future FDA submissions.
- New Drug Application Plans: The company plans to submit a new drug application for azetukalner to the U.S. FDA in Q3 2026, with CEO Ian Mortimer stating that the trial results “exceeded expectations,” potentially reshaping the epilepsy treatment landscape to meet the needs of 50% of patients seeking better control.
- Positive Market Reaction: Following the trial data announcement, Xenon's stock surged 50%, with Jefferies and RBC Capital raising their price targets to $100 and $80 respectively, reflecting strong market confidence in azetukalner and its significant sales potential in the future.
- Competitor Dynamics: Despite Biohaven's opakalim having safety disadvantages, Raymond James maintains a ‘Strong Buy’ rating, anticipating pivotal trial results in H2 2026 that will further clarify its market positioning.
See More
Biohaven Shares Fluctuate Following Positive Study Data
- Positive Clinical Data: Xenon Pharmaceuticals' X-TOLE2 study demonstrated a median percentage change of -42.7% in monthly focal onset seizure frequency for azetukalner at the 25 mg dose, providing short-term support for Biohaven's stock, despite its own BHV-7000 failing to meet primary endpoints in a Phase 2 trial for depression.
- Stock Performance Analysis: Biohaven shares peaked at $12.52 during premarket trading on Monday but fell back to $9.93, which is 12.5% below its 20-day simple moving average, indicating a bearish trend in the short term, with a 64.95% decline over the past year.
- Technical Indicator Insights: The current Relative Strength Index (RSI) stands at 36.10, indicating neutral territory, while the MACD value of -0.3294 is below its signal line of -0.1633, suggesting bearish pressure on the stock, with key resistance at $10.50 and support at $9.50.
- Analyst Ratings and Targets: While Biohaven's stock carries a Buy rating with an average price target of $30.36, recent actions show HC Wainwright & Co. lowering its target to $10.00, while RBC Capital raised its target to $23.00, reflecting differing analyst perspectives on the stock's outlook.
See More
DAFNA Capital Management Increases Biohaven Stake
- Increased Holdings: DAFNA Capital Management acquired 720,000 shares of Biohaven in Q4 2025, with an estimated trade value of $8.92 million, indicating confidence in the company's future potential.
- Value Appreciation: By quarter-end, DAFNA's total stake value reached $10.78 million, up $7.25 million from the previous period, reflecting both stock price movements and the addition of new shares.
- Strategic Focus: Biohaven is cutting spending and narrowing its focus to three late-stage programs; despite a net loss of approximately $739 million last year, the company is undergoing a strategic transformation aimed at enhancing market competitiveness.
- Improved Liquidity: With about $322 million in cash at year-end and additional capital raised thereafter, Biohaven's financial position appears more stable than its stock price suggests, providing potential opportunities for future growth.
See More
DAFNA Capital Increases Biohaven Stake by 720,000 Shares
- Share Increase: DAFNA Capital increased its stake in Biohaven by 720,000 shares during Q4 2025, with an estimated transaction value of $8.92 million, reflecting confidence in the company's future potential.
- Value Growth: Following this purchase, Biohaven's total stake value rose to $10.78 million, an increase of $7.25 million from the previous period, indicating the dual impact of stock price movements and additional shares.
- Portfolio Dynamics: Biohaven now represents 2.51% of DAFNA's reportable U.S. equity assets, highlighting its significance in the portfolio despite its overall poor performance.
- Company Transformation: Despite a net loss of approximately $739 million last year, Biohaven is focusing on three late-stage programs expected to yield important data this year, showcasing the company's potential and strategic adjustments during its transition.
See More
Biohaven Completes Enrollment in Obesity Treatment Clinical Trial
- Clinical Trial Enrollment Completed: Biohaven announced the completion of enrollment for its Phase 2 trial of taldefgrobep alfa, targeting approximately 150 participants, with topline data expected in the second half of 2026, potentially introducing a new treatment option for obesity.
- Efficacy Assessment Design: The trial employs a randomized, double-blind, placebo-controlled design to evaluate the monotherapy efficacy of taldefgrobep, primarily measuring weight change over 24 weeks, aiming to provide more effective treatment options for obese patients and potentially altering current treatment standards.
- Good Safety and Tolerability: Taldefgrobep has demonstrated good tolerability in over 700 clinical trial participants, with low rates of serious adverse events, indicating a promising outlook for its application in chronic weight management and positioning it as a next-generation obesity treatment.
- Innovative Mechanism and Market Potential: Taldefgrobep shows significant potential for improving body weight and fat mass by inhibiting activin receptor signaling, and its combination with GLP-1 agonists may open new market opportunities in obesity treatment, addressing the growing global demand for effective obesity therapies.
See More
Biohaven Completes Enrollment in Obesity Treatment Study
- Enrollment Completion: Biohaven announced the completion of enrollment in its Phase 2 study of taldefgrobep alfa for obesity, with topline data expected in the second half of 2026, marking a significant advancement in the company's obesity treatment efforts.
- Efficacy Assessment: The study will evaluate the efficacy of once-weekly and once-monthly taldefgrobep monotherapy, targeting approximately 150 participants, with primary measures focusing on weight change, reflecting the company's ongoing commitment to obesity treatment.
- Favorable Safety Profile: Taldefgrobep has demonstrated a favorable safety and tolerability profile in over 700 trial participants, with low rates of adverse events, establishing a solid foundation for its application in chronic weight management.
- Market Potential: The novel mechanism of taldefgrobep may provide significant benefits in fat reduction and muscle gain, with Biohaven believing it could offer new treatment options for obesity patients, further driving growth in the biopharmaceutical sector.
See More
Xenon Plans New Drug Application Submission
- Trial Results Exceed Expectations: Xenon announced that its azetukalner showed a median percent change of 53.2% in monthly focal onset seizure frequency at the 25 mg dose, significantly outperforming the placebo's 10.4%, which not only validates the drug's efficacy but also lays a solid foundation for future FDA submissions.
- New Drug Application Plans: The company plans to submit a new drug application for azetukalner to the U.S. FDA in Q3 2026, with CEO Ian Mortimer stating that the trial results “exceeded expectations,” potentially reshaping the epilepsy treatment landscape to meet the needs of 50% of patients seeking better control.
- Positive Market Reaction: Following the trial data announcement, Xenon's stock surged 50%, with Jefferies and RBC Capital raising their price targets to $100 and $80 respectively, reflecting strong market confidence in azetukalner and its significant sales potential in the future.
- Competitor Dynamics: Despite Biohaven's opakalim having safety disadvantages, Raymond James maintains a ‘Strong Buy’ rating, anticipating pivotal trial results in H2 2026 that will further clarify its market positioning.
See More
Biohaven Shares Fluctuate Following Positive Study Data
- Positive Clinical Data: Xenon Pharmaceuticals' X-TOLE2 study demonstrated a median percentage change of -42.7% in monthly focal onset seizure frequency for azetukalner at the 25 mg dose, providing short-term support for Biohaven's stock, despite its own BHV-7000 failing to meet primary endpoints in a Phase 2 trial for depression.
- Stock Performance Analysis: Biohaven shares peaked at $12.52 during premarket trading on Monday but fell back to $9.93, which is 12.5% below its 20-day simple moving average, indicating a bearish trend in the short term, with a 64.95% decline over the past year.
- Technical Indicator Insights: The current Relative Strength Index (RSI) stands at 36.10, indicating neutral territory, while the MACD value of -0.3294 is below its signal line of -0.1633, suggesting bearish pressure on the stock, with key resistance at $10.50 and support at $9.50.
- Analyst Ratings and Targets: While Biohaven's stock carries a Buy rating with an average price target of $30.36, recent actions show HC Wainwright & Co. lowering its target to $10.00, while RBC Capital raised its target to $23.00, reflecting differing analyst perspectives on the stock's outlook.
See More
